Breast Cancer Clinical Trials

Ongoing Breast Cancer Trials @ NCIS - Patient Recruitment

Protocol Title and Number
Phase II randomized study of doxorubicin and cyclophosphamide with or without intermittent sunitinib in the first-line treatment of locally advanced or metastatic breast cancer patients with measurable primary breast tumour
A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in patients with HER2-negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pathway activation
A prospective clinical study to clarify the relationship between the genotype for the drug-metabolizing enzyme, CYP2D6, and the therapeutic effects of preoperative tamoxifen therapy
A multicentre, randomised, phase III study of vinflunine plus capecitabine versus capecitabine alone in patients with advanced beast cancer previously treated with an anthracycline and a taxane
NeoPHOEBE: Pi3k inhibition in Her2 OverExpressing Breast cancEr: A phase II, randomized, parallel cohort, two stage, double-blind, placebo-controlled study of neoadjuvant trastuzumab versus trastuzumab + BKM120 in combination with weekly paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer
A study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in patients with HER2+ Metastatic breast cancer who have received two or more prior HER2 directed regimens in the metastatic setting (NALA)
Phase I/II study of expanded, activated autologous natural killer cell infusions with trastuzumab for patients with HER2+ breast and gastric cancer
A study comparing denosumab with zoledronic acid (Zometa) in subjects of Asian ancestry with advanced breast cancer metastases to bone
PREventing CHemotherapy Induced Neuropathy (PreChIN)
A randomized, multicenter, open-label, phase 3 trial comparing trastuzumab plus pertuzumab plus a taxane following anthracyclines versus trastuzumab emtasine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-postive primary breast cancer
A phase Ib/II study of LEE011 in combination with fulvestrant and BYL719 or BKM120 in the treatment of postmenopausal women with hormone receptor positive, HER2 negative locally recurrent or advanced metastatic breast cancer


For more information about ongoing Breast Cancer Clinical Trials, kindly contact